Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles.

Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, Bhattacharya R, Robertson JD, Rotello VM, Reid JM, Mukherjee P. · 2011

Read Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. by Arvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, Bhattacharya R, Robertson JD, Rotello VM, Reid JM, Mukherjee P. (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3172229.txt.

Introduction

Rochelle Arvizo and colleagues showed how surface charge steers medical nanoparticles through the body in a 2011 paper in PLoS ONE. Tiny engineered particles promise better cancer detection and drug delivery, but their travel behaviour was poorly mapped. The team made a matched family of gold particles differing only in surface coating: neutral, balanced-charge, negative, or positive, and injected them into mice by vein or belly.

Neutral and balanced particles circulated far longer than charged ones, whose blood levels fell quickly. The long travellers also entered tumours more, apparently by leaking passively through tumour vessels, while charged particles were cleared into organs sooner. The results give designers a simple rule: keep the surface uncharged to buy time and tumour access.

Catalog record

CREATORArvizo RR, Miranda OR, Moyano DF, Walden CA, Giri K, Bhattacharya R, Robertson JD, Rotello VM, Reid JM, Mukherjee P.
YEAR2011
COLLECTIONPAPERS
FORMATTXT
FILE SIZE29 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3172229

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered Nanoparticles By Rochelle R Arvizo, Oscar R Miranda, Daniel F Moyano, Chad A Walden, Karuna Giri, Resham Bhattacharya, J David Robertson, Vincent M Rotello, Joel M Reid, Priyabrata Mukherjee, Sujit Basu Published in: PLoS ONE DOI: 10.1371/journal.pone.0024374 ABSTRACT Abstract Background Inorganic nanoparticles provide promising tools for biomedical applications including detection, diagnosis and therapy. While surface properties such as charge are expected to play an important role in their in vivo behavior, very little is known how the surface chemistry of nanoparticles influences their pharmacokinetics, tumor uptake, and biodistribution. Method/Principal Findings Using a family of structurally homologous nanoparticles we have investigated how pharmacological properties including tumor uptake and biodistribution are influenced by surface charge using neutral (TEGOH), zwitterionic (Tzwit), negative (TCOOH) and positive (TTMA) nanoparticles. Nanoparticles were injected into mice (normal and athymic) either in the tail vein or into the peritoneum. Conclusion Neutral and zwitterionic nanoparticles demonstrated longer circulation time via both IP and IV administration, whereas negatively and positively charged nanoparticles possessed relatively short half-lives. These pharmacological characteristics were reflected on the tumor uptake and biodistribution of the respective nanoparticles, with enhanced tumor uptake by neutral and zwitterionic nanoparticles via passive targeting. INTRODUCTION The limited solubility, stability, and short circulation time of traditional therapeutic agents can introduce side effects and unwanted accumulation of therapeutics into non-diseased tissue [1]. Multimodal nanoparticles, polymer-drug conjugates, monoclonal antibodies and immunoconjugates provide a means of increasing therapeutic efficacy [2], while also providing new therapeutic and imaging modalities [3]. The diversity of available structures and core materials [4], [5] coupled with sub-cellular size and biocompatibility have generated numerous applications of these materials in fields ranging from delivery [6]–[8] and imaging [9], to photothermal ablation of tumors [10], [11]. Key issues for the creation of effective nanotherapeutics include (i) overcoming biological barriers, (ii) specific accumulation of the therapeutic at the target site (i.e, targeting), and (iii) preventing rapid clearance [12]. While there have been a number of studies on the effects of particle size on biodistribution [13], little is known about the effect of surface charge on biodistribution and pharmacokinetics of nanoparticles, as these studies have generally used neutral poly(ethylene glycol) (PEG) functionalization [14]. This “stealth” coverage decreases the rate of opsonization, providing more efficient transport to the target tissue, e.g. tumor. The neutral coating provided by PEG coverage provides one route to enhanced bioavailability. Charged systems including zwitterionic surfaces [15], however, provide an alternative means of dictating the bioavailability of nanomaterials. To date, there has not been a detailed statistically robust investigation on how the surface charge of nanosystems impact their biodistribution, pharmacokinetics and tumor uptake. In the current study, we systematically investigate the role of the surface charge of engineered gold nanoparticles in dictating the pharmacokinetics, and hence the biodistribution and tumor uptake of these nanomaterials. As the biodistribution of drug carriers is dependent upon the route of administration [16], we administered these particles using both intravenous (IV) and intraperitoneal (IP) routes [17]. We first assessed how surface charge impacts pharmacokinetics (PK) and biodistribution of the particles in a mouse model, demonstrating that surface charge determines circulation time of gold nanoparticles in the blood and tumor uptake through passive targeting. Through these studies, we reveal that surface charge and mode of administration has tremendous consequences on nanoparticle behavior in vivo, thus providing insight for the improved design in nanoparticle therapeutics. RESULTS Nanoparticle Fabrication Our studies used gold nanoparticles (AuNP) featuring 2 nm diameter cores, with overall hydrodynamic diameters of ∼9–10 nm. As shown in Figure 1, all nanoparticles contain a hydrophobic interior that confers stability [18] and a tetra(ethylene glycol) functionality to provide compatibility and solubility in cell culture media and other biological fluids. The interactions of these particles are dictated by the choice of headgroups, facilitating the determination of structure-activity correlations [19]. These particles are also exceptionally stable in biofluids [20], rendering them useful as drug delivery vehicles [21] and in sensing [22]. To provide a concise study of the role of charge in bioavailability, AuNPs featuring anionic, cationic and zwitterionic particle surfaces were fabricated using ligands having the appropriate headgroups [23]. These particles have been shown to be stable against aggregation in serum and have relatively low toxicities in both in vitro cell assays [24] and in fish [25]. Central to our studies, the common structure shared by these particles allows direct assessment of the role of charge on in vivo behavior (see Figure S1). [Figure: Structural representation of gold nanoparticles (2 nm core diameter) used.Gold nanoparticles (AuNPs) of different surface charges were generated by chemical modification of the terminal portion of the ligand bonded to the nanoparticle core. Four types of AuNPs were used neutral (TEGOH), positive (TTMA), negative (TCOOH) and zwitterionic (TZwit). The surface charge was measured by zeta potential.] Plasma Pharmacokinetics is affected by nanoparticle surface charge The plasma dispositions of the AuNPs were characterized in male CD1 mice after IV and IP administration. Plasma concentration-time profiles for each AuNP are illustrated in Figure 2, with the pharmacokinetic parameters are summarized in Table 1. High peak plasma concentrations (Cmax) >80 mg/ml were achieved with IV injection of the negative (TCOOH), neutral (TEGOH) and zwitterionic (TZwit) particles, while a 10-fold lower peak plasma concentration was achieved with the positive (TTMA) particles (Table 1). Following IV injection, high plasma clearance was observed for the negative (TCOOH) and positive (TTMA) charged AuNPs (0.0739 µg/ml/min and 0.170 µg/ml/min, respectively) such that the plasma concentrations fell below 1 mg/ml within 15 minutes after injection (Figure 1A). In contrast, plasma clearance for the neutral (TEGOH) and zwitterionic (TZwit) particles was substantially lower (0.00605 µg/ml/min and 0.00561 µg/ml/min, respectively) such that plasma concentrations remained above 1 µg/ml 24 hours after injection (Figure 1A). After IP injection, low concentrations (<1 µg/ml) of the negative (TCOOH) and positive (TTMA) AuNPs were detected in the circulation (Figure 2B). In marked contrast, the neutral (TEGOH) and zwitterionic (TZwit) AuNPs rapidly entered into circulation, with peak concentrations above 10 µg/ml achieved 1.5 and 3 hours, respectively. As with the IV injection, plasma concentrations of the neutral (TEGOH) and zwitterionic (TZwit) AuNPs remained above 1 µg/ml 24 hours after injection (Figure 2B) and bioavailability values for these AuNP were high (77% and 70%, respectively). From these results, it is apparent that nanoconjugates with neutral and zwitterionic properties maximize the circulation time. [Figure: Plasma profiles for gold nanoparticles.Normal mice were injected either (A) intravenously or (B) intraperitoneally. Data points are the mean +/− SEM from n = 3 animals.] [Table: AuNP Pharmacokinetics Summary.] Tumor Uptake of AuNPs is related to circulation resident time Passive targeting of nanomaterials via the enhanced permeability and retention (EPR) effect is dependent on their blood resident time [26]. Our hypothesis was that the neutral and zwitterionic nanoconjugates would exhibit increased tumor uptake relative to negative and positively charged analogs. As expected, the nanoparticles with a long retention time in circulation (TEGOH and TZwit) accumulated more efficiently into the tumor (Figure 3). After 24 hours post-injection (200 µg per mouse via tail vein or intraperitoneal), subcutaneously implanted ovarian tumor-bearing athymic nude mice were euthanized and the tumors were analyzed for gold content. The TZwit and TEGOH nanoparticles had substantially higher tumor

Read the complete text